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Abstract
Background—The two common sialic acid (Sia) in mammals are N-Acetylneuraminic acid 
(Neu5Ac) and its hydroxylated form N-Glycolylneuraminic acid (Neu5Gc). Unlike most 
mammals, humans cannot synthesize Neu5Gc that is considered foreign and recognized by 
circulating antibodies. Thus, Neu5Gc is a potential xenogenic carbohydrate antigen in 
bioprosthetic heart valves (BHV) that tend to deteriorate in time within human patients.
Methods—We investigated Neu5Gc expression in non-engineered animal-derived cardiac tissues 
and in clinically used commercial BHV, and evaluated Neu5Gc immunogenicity on BHV through 
recognition by human anti-Neu5Gc IgG.
Results—Neu5Gc was detected by immunohistochemistry in porcine aortic valves and in porcine 
and bovine pericardium. Qualitative analysis of Sia-linkages revealed Siaα2–3>Siaα2–6 on 
porcine/bovine pericardium while the opposite in porcine aortic/pulmonary valve cusps. Similarly, 
*Corresponding author address: Department of Cell Research & Immunology, The George S. Wise Faculty of Life Sciences, Tel-
Aviv University, Tel Aviv 69978 Israel. Tel: +972-3-640-6737. Fax: +972-3-642-2046. vkaravani@post.tau.ac.il. 
HHS Public Access
Author manuscript
Xenotransplantation. Author manuscript; available in PMC 2017 September 09.
Published in final edited form as:













six commercial BHV containing either porcine aortic valve or porcine/bovine/equine pericardium 
revealed Siaα2–3>Siaα2–6 expression. Quantitative analysis of Sia by HPLC showed porcine/
bovine pericardium express four-fold higher Neu5Gc levels compared to the porcine aortic/
pulmonary valves, with Neu5Ac at six-fold over Neu5Gc. Likewise, Neu5Gc was expressed on 
commercial BHV (186.3±16.9 pmol Sia/μg protein), with Neu5Ac at eight-fold over Neu5Gc. 
Affinity-purified human anti-Neu5Gc IgG showing high specificity towards Neu5Gc-glycans (with 
no binding to Neu5Ac-glycans) on a glycan microarray, strongly bound to all tested commercial 
BHV, demonstrating Neu5Gc immune recognition in cardiac xenografts.
Conclusions—We conclusively demonstrated Neu5Gc expression in native cardiac tissues, as 
well as in six commercial BHV. These Neu5Gc xeno-antigens were recognized by human anti-
Neu5Gc IgG, supporting their immunogenicity. Altogether, these findings suggest BHV-Neu5Gc/
anti-Neu5Gc may play a role in valve deterioration warranting further investigation.
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Introduction
Heart valve diseases include several pathologies prevalent in ~2–3% of the population in 
developed countries [1,2]. Valvular stenosis is frequently diagnosed and result in valve 
narrowing that restricts normal blood flow with no available medicinal treatment but valve 
replacement [2]. Prosthesis selection includes either bioprosthetic or mechanical heart valves 
(BHV or MHV, respectively), however the latter requires supporting long-term 
anticoagulation. Some studies found better long-term survival for patients receiving the 
latest generation MHV over BHV [3], while others demonstrated equal benefit, but with 
higher incidence of stroke and bleeding in patients receiving MHV [4]. Use of BHV for 
younger patients is controversial [3-5], yet constantly increasing [3,6,7] especially with the 
relative success of the less invasive valve-in-valve trans catheter techniques [8,9] as a later 
procedure if BHV deteriorates. Given the tradeoff between the risk of reoperation because of 
BHV degeneration and the risk associated with long-term anticoagulation, most recent 
guidelines emphasize patients’ choice regarding the type of valve. However, MHV remains 
the recommended prosthesis in patients below the age of 60 if anticoagulation therapy can 
be properly maintained.
BHV made of animal-derived cardiac tissues (i.e. pericardium or porcine heart valve) are 
less durable compared to mechanical valves, largely due to structural valve deterioration 
(SVD) [10,11], especially in patients below 60 years of age [12,13]. In addition, valve 
deterioration is observed earlier in younger BHV recipients (under the age of 50), and high 
mortality is associated with reoperation due to SVD [5]. The immune response towards 
xeno-antigens has been suggested to participate in bioprosthesis SVD [14,15]. Galα1–3Gal 
(α-Gal) is widely accepted as an immunogenic glycan to which the human immune system 
is highly responsive [16,17], and this antigen was recently identified in BHV [18,19]. All 
humans have circulating anti-α-Gal antibodies that respond to this glyco-epitope on 
xenogenic tissues [16,20,21] causing in turn an antibody-mediated inflammation that may 
contribute to BHV degeneration [5,18]. However, studies using α-Gal-knockout tissues 
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reduced immune response against BHV but did not eliminate it [5,22,23], prompting search 
for other non-Gal immunogens in BHV [5,24-26]. One such candidate non-Gal immunogen 
had been suggested to be the non-human sialic acid N-Glycolylneuraminic acid (Neu5Gc) 
carbohydrate xeno-antigen [1,23,26-30], that shares some similarities with α-Gal (neither 
are synthesized in humans due to inactivation of specific genes and the humoral response 
encompass IgA, IgG and IgM) [27].
Sialic acids (Sia) are 9-carbon backbone α-keto sugars covering the tips of sugar chains 
(glycans) on cell surface glycoproteins and glycolipids (glycoconjugates). The two most 
common Sias in mammals are N-Acetylneuraminic acid (Neu5Ac) and its hydroxylated 
form Neu5Gc. However, unlike most other mammals, humans cannot produce Neu5Gc due 
to a deletion in the CMAH gene encoding the CMP-Neu5Ac hydroxylase [31,32]. 
Therefore, Neu5Gc is foreign to humans, yet dietary consumption of mammalian food 
products (e.g. red meat and milk products) result in Neu5Gc intake and its expression on the 
surface of some human cells [32,33]. Various Neu5Gc-containing glycans (on human cells 
from dietary intake or intrinsically in xenografts) are recognized as foreign by the human 
immune system resulting in a diverse anti-Neu5Gc immune response [30,34] that can lead to 
chronic inflammation (e.g. in cancer and vascular disease) [35-37], and last for many years 
even after a short exposure to animal-derived tissues [38]. Neu5Gc had been detected in 
various porcine organs [28], and more recently described in porcine heart valves by 
immunohistochemistry [29] and mass spectrometry of glycoproteins [39], but not of 
glycolipids [24]. Therefore, Neu5Gc may be a non-Gal xeno-antigen in BHV potentially 
recognized by circulating human anti-Neu5Gc antibodies, thereby likely contributing to 
BHV structural deterioration. Here we aimed to qualitatively and quantitatively investigate 
Neu5Gc expression in various animal-derived cardiac tissues and in commercial BHV used 
in the clinic. We further tested the binding of highly specific human anti-Neu5Gc IgG 
antibodies to Neu5Gc-xeno-antigens present on all tested commercial BHV. Altogether these 




Human sera were obtained from the Israeli Blood Bank and used in accordance with the 
Helsinki declaration and Tel Aviv University Institutional Review Board.
Tissue samples
Native porcine and bovine tissues were obtained from a local slaughterhouse. Pericardium 
and valve cusps (aortic and pulmonary) were carefully dissected and kept frozen at −20 °C 
separately until analysis, or fixed for immunohistochemistry as detailed. The commercial 
bioprostheses used in the study were kindly donated by the corresponding producing 
companies (Medtronic, Sorin, St. Jude Medical).
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We used affinity-purified polyclonal chicken anti-Neu5Gc IgY [40] (Biolegend), horse 
radish peroxidase (HRP)-streptavidin , Cy3-streptavidin, HRP-goat-anti-human IgG, Cy3-
goat-anti-human IgG (H+L), biotinylated donkey-anti-chicken IgY, HRP-AffiniPure donkey-
anti-chicken IgY (IgG)(H+L), Cy3-donkey-anti-chicken IgY (IgG)(H+L) (Jackson 
ImmunoResearch), biotinylated GSL I – isolectin B4 (IB4), biotinylated SNA (Sambucus 
nigra) and biotinylated MAL-II (Maackia amurensis lectin II) (Vector Labs). All antibodies 
and lectins were used at optimized saturating concentrations.
Immunohistochemistry
Porcine heart valve cusps and porcine and bovine pericardia (the full thickness parietal 
tissue) as well as porcine kidney (positive control) were fixed in buffered paraformaldehyde. 
Immunostaining was performed on 4 μm paraffin sections using cold water fish gelatin 
(Sigma) in PBS buffer containing 0.1% Triton X-100 as blocking reagent. Primary antibody 
was the affinity-purified polyclonal chicken anti-Neu5Gc IgY [40] (Biolegend) in serial 
dilutions where a dilution of 1:2000 was found to be optimal. Secondary antibody was 
biotinylated-donkey anti-chicken IgY (1:500; Jackson ImmunoReserach) detected by HRP-
streptavidin (Jackson ImmunoResearch) followed by DAB reagent (Dako). Positive control 
tissue was porcine kidney and negative controls were obtained by omitting the primary 
antibody.
Tissue homogenization
Porcine, bovine or commercial BHV portions were prepared from frozen or refrigerated 
tissue samples, respectively. Tissues were thawed and weighed. Samples (~16–35 mg) were 
then finely sliced and dissolved in 1 ml TRIS-HCl buffer (50 mM pH5.5) with 10 mM of 
Ca2+. The solution was thoroughly vortexed for 30 seconds and then 2 mg/ml of collagenase 
type 2 (Sigma) was added and the mixture was incubated at 37 °C for 1 hour while shaking 
at 220 rpm. Samples were then put on ice and sonicated with a probe sonicator (Sonic 
dismembrator, Fisher scientific) three times at a medium power, each for 10 seconds with 
30-second intervals incubation on ice. Sonicated solutions together with non-homogenized 
tissue were then inserted to a glass dounce tissue grinder (2 ml; Sigma) and homogenized 
with a loose pestle then with a tight pestle (10 times each). Of note, the fresh tissues were 
fully disrupted while BHV samples were more sturdy. The protein content in the 
homogenate was evaluated by a standard BCA assay according to manufactures’ protocol 
(Pierce). The homogenate was kept at −20 °C until use.
Sialic acid analysis by DMB-HPLC
Sia content of tissue and BHV homogenates was analyzed. Sias were released from 
glycoconjugates by acid hydrolysis; either by hydrolysis that removes O-Acetylation, with 
0.1 M of H2SO4 for 1.5 hours (neutralizing with 0.1 M of NaOH) or by hydrolysis that 
maintains O-Acetylation with 2 M of acetic acid for three hours, both at 80 °C [41]. Free 
Sias were then derivatized with 1,2-diamino-4,5-methylenedioxybenzene (DMB; Sigma) for 
2.5 hours at 50 °C, separated by Microcon-10 centrifugal filters and analyzed by 
fluorescence detection on reverse-phase high pressure liquid chromatography (DMB-HPLC) 
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(Hitachi HPLC Chromaster). HPLC run was on C18 column (Phenomenex C18 Gemini 250 
× 4.6 mm) at 24 °C in running buffer [84.5% ddH2O, 8.5% acetonitrile, 7% methanol 
(Merck)] for 60 minutes (min) at a flow rate of 0.9 ml/min. Quantification of Sias was done 
by comparison with known quantities of DMB-derivatized Neu5Ac [41].
ELISA
Binding of human sera, lectins or antibodies to tissue homogenates was tested by ELISA as 
described [34]. Tissue homogenates (entire crude suspension) were coated at optimized 
equal protein concentrations in duplicates at 2 μg/well in 50 mM sodium carbonate-
bicarbonate buffer, pH 9.5 onto 96-well microtiter plates (Costar, Corning) and plates were 
incubated overnight at 4 °C. Wells were blocked for 1 hour at room temperature with 
blocking buffer [PBS pH 7.4, 1% ovalbumin (Grade V, Sigma)]. Wells were aspirated and 
incubated with diluted primary antibody 100 μl/well in the same blocking buffer for two 
hours at room temperature (1:100 diluted human or mouse serum samples, chicken anti-
Neu5Gc IgY at 1:1000, biotinylated SNA or MAL-II at 1μg/ml). The plates were washed 
three times with PBST (PBS pH 7.4, 0.1% Tween) and subsequently incubated for 1 hour at 
room temperature with HRP-conjugated secondary antibody in PBS (respectively: HRP-goat 
anti-human IgG 0.11 μg/ml, goat-anti-mouse IgG 0.16 μg/ml, HRP-donkey-anti-chicken IgY 
0.26 μg/ml and HRP-streptavidin 0.1 μg/ml). After washing three times with PBST, wells 
were developed with 140 μl of O-phenylenediamine in 100 mM citrate-PO4 buffer, pH 5.5, 
and the reaction stopped with 40 μl of H2SO4 (4 M). Absorbance was measured at 490 nm 
on SpectraMax M3 (Molecular Devices). Specific binding was defined by subtracting the 
background readings obtained with the secondary antibody only on coated wells.
Affinity purification of human anti-Neu5Gc IgG
Pooled human IgG, from clinical therapeutic IVIG leftovers (GAMMAGARD LIQUID, 
Baxter), was kindly provided by Dr. Adriana H. Tremoulet from the Rady Children's 
Hospital, San Diego, USA. Polyclonal human anti-Neu5Gc IgG were affinity-purified from 
IVIG on sequential columns with immobilized human serum and chimpanzee serum as 
previously described [34]. Chimpanzee sera were obtained from the local zoo only during 
routine maintenance procedures and kindly provided by Dr. Gillad Goldstein, curator of the 
Zoological Center Tel Aviv, Safari Park (Israel) and Dr. Nili Avni-Magen, Head Veterinarian 
and Zoological Director of The Tisch Family Zoological Gardens in Jerusalem (Israel).
Biotinylation of affinity-purified human anti-Neu5Gc IgG
Antibodies were biotinylated according to the manufacturer's instruction (EZ-Link™ Sulfo-
NHS Biotin kit, Pierce). Briefly, 0.5 ml of purified anti-Neu5Gc IgG 0.5 mg/ml were 
supplemented with 3 μl 10 mM of sulfo-NHS-biotin and incubated on ice for two hours. 
Non-reacted Sulfo-NHS-biotin was removed using zeba-spin gel filtration columns (Pierce).
Sialoglycan microarray fabrication
Arrays were printed on epoxide-derivatized Corning slides as described (Array1 [42]) with 
some modifications. Arrays were fabricated with NanoPrint LM-60 Microarray Printer 
(Arrayit) on epoxide-derivatized slides (Corning) with 16 sub-array blocks on each slide. 
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Glycoconjugates were distributed into one 384-well source plates using 4 replicate wells per 
sample and 8 μl per well (Version 1.0). Each glycoconjugate was prepared at 100 μM in an 
optimized print buffer (300 mM phosphate buffer, pH 8.4). To monitor printing quality, 
replicate-wells of human IgG (Jackson, at 200, 100, 50, 25, 12.5, 6.25 ng/μl in PBS+10% 
glycerol) and AlexaFlour-555-Hydraside (Invitrogen, at 1 ng/μl in 178 mM phosphate buffer, 
pH 5.5) were used for each printing run. The arrays were printed with four 946MP3 pins (5 
μm tip, 0.25 μl sample channel, ~100 μm spot diameter; Arrayit). Each block (sub-array) has 
17 spots/row, 20 columns with spot to spot spacing of 225 μm. The humidity level in the 
arraying chamber was maintained at about 66% during printing. Printed slides were left on 
arrayer deck over-night, allowing humidity to drop to ambient levels (40-45%). Next, slides 
were packed, vacuum-sealed and stored in a desiccant chamber at room temperature (RT) 
until used.
BHV microarray fabrication
Arrays were printed with NanoPrint LM-60 Microarray Printer (Arrayit) on epoxide-
derivatized slides (Corning) with 16 sub-array blocks on each slide. Homogenates of BHV 
were distributed into one 384-well source plates using 4 replicate wells per sample and 8 μl 
per well. Each BHV's homogenate was centrifuged and the supernatant diluted in PBS pH 
7.4 to 100 ng/μl. To monitor printing quality, human IgG (Jackson, 40 ng/μl in PBS+10% 
glycerol) and AlexaFlour-555-Hydraside (Invitrogen, at 1 ng/μl in 178 mM phosphate buffer, 
pH 5.5) were used for each printing run. The arrays were printed with one 946MP3 pin (5 
μm tip, 0.25 μl sample channel, ~100 μm spot diameter; Arrayit). Each block (sub-array) has 
14 rows, 6 columns with spot to spot spacing of 225 μm. The humidity level in the arraying 
chamber was maintained at about 70% during printing. Printed slides were left on arrayer 
deck over-night, allowing humidity to drop to ambient levels (40–45%). Next, slides were 
packed, vacuum-sealed and stored in a desiccant chamber at RT until used.
Sialoglycan microarray binding assay
Slides were developed and analyzed as previously described [42]. Slides were rehydrated 
with dH2O and incubated for 30 min in a staining dish with 50°C pre-warmed ethanolamine 
(0.05 M) in Tris-HCl (0.1 M, pH 9.0) to block the remaining reactive epoxy groups on the 
slide surface, then washed with 50 °C pre-warmed dH2O. Slides were centrifuged at 200×g 
for three min then fitted with ProPlate™ Multi-Array 16-well slide module (Invitrogen) to 
divide into the sub-arrays (blocks). Slides were washed with PBST, aspirated and blocked 
with 200 μl/sub-array of blocking buffer (PBS/OVA, 1% w/v ovalbumin, Sigma in PBS, pH 
7.3) for 1 hour at RT with gentle shaking. Next, the blocking solution was aspirated and 200 
μl/ block of primary detection diluted in PBS/OVA was added: polyclonal affinity-purified 
human anti-Neu5Gc IgG (from IVIG) at 40 μg/ml, biotinylatedlectins (SNA/MAL-II/IB4; 20 
μg/ml). Primary detections were incubated with gentle shaking for 2 hours at RT. Slides 
were washed three times with PBST (PBS, 0.1% Tween) then with PBS for 10 min/wash 
with shaking. Bound antibodies were detected by incubating with secondary detection 
diluted in PBS, 200 μl/block at RT for 1 hour: Cy3-goat-anti-human IgG (H+L) (0.4 μg/ml) 
or Cy3-streptavidin (1.2 μg/ml). Slides were washed three times with PBST then with PBS 
10 min/wash followed by removal from ProPlate™ Multi-Array slide module and 
immediately dipping slide in a staining dish with dH2O for 10 min with shaking, then 
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centrifuged at 200×g for 3 min. Dry slides were vacuum-sealed and stored in dark until 
scanning.
Array slide processing
Processed slides were scanned and analyzed as described at 10 μm resolution with a 
Genepix 4000B microarray scanner (Molecular Devices) using 350 gain [42]. Image 
analysis was carried out with Genepix Pro 6.0 analysis software (Molecular Devices). Spots 
were defined as circular features with a variable radius as determined by the Genepix 
scanning software. Local background subtraction was performed.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5.0, and described in context in 
the figure legends.
Results
Expression of Neu5Gc in native untreated porcine and bovine cardiac tissues
To evaluate Neu5Gc expression in porcine aortic valvular cusp and porcine and bovine 
pericardium, the main source of biological tissues for commercial BHV, 
immunohistochemistry analysis was performed using a highly specific polyclonal antibody 
that recognize multiple Neu5Gc-containing glycans [40,42]. Anti-Neu5Gc antibody showed 
a clear staining of the porcine valve cusp endothelium (Figure 1B) and a very faint staining 
in the cusp matrix tissue under the endothelium. Porcine pericardium (Figure 1C) showed 
staining of the entire matrix tissue with an increased staining of the mesothelial cells. The 
endothelium of a small artery (Figure 1C) is positive while the arterial muscular cells are 
negative. Bovine pericardium (Figure 1D) shows similar staining to the porcine pericardium 
with diffused staining of the matrix and strong staining of the epicardial and vascular 
endothelial cells. The negative controls, omitting the primary antibody, were always 
completely negative (Figure 1A). Porcine kidney positive control tissue (not shown) showed 
strong anti-Neu5Gc staining of all vascular endothelial cells (artery, glomerular- and 
peritubular-capillaries). The tubular cell brush border was positive and a weak granular 
staining of the tubular cell cytoplasm was also seen. All artery muscular cells were 
completely negative, as seen for the pericardial small arteries in Figures 1C–D, showing that 
the diffuse staining of the pericardium matrix is not due to non-specific background staining. 
Altogether, Neu5Gc seems to be intrinsically expressed on all tested animal-derived cardiac 
tissues that make up various commercial BHV.
Characterization of Neu5Gc antigen in native untreated porcine and bovine cardiac tissues
Neu5Ac and Neu5Gc are Sia normally covering the tips of glycans on various glycoproteins 
and glycolipids on the cell surface [32]. Sias are attached to underlying carbohydrate core 
chains via α2–3 or α2–6 linkages (namely, Sia carbon C-2 attached to C-3 or C-6 of 
galactose or N-Acetylgalactosamine). To further characterize Sia expression and their core 
saccharide linkage in xenogenic cardiac tissues of relevance for BHV, we analyzed porcine 
aortic and pulmonary valve cusps, and porcine and bovine pericardium (Figure 2). The 
tissues were partially homogenized and Sia distribution investigated by ELISA using anti-
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Neu5Gc IgY and Sia-binding lectins that can differentially recognize glycans carrying 
Siaα2–3 (MAL-II) or Siaα2–6 (SNA) [42]. This revealed that all tissues express Neu5Gc 
(Figure 2), supporting the immunohistochemistry analysis. Furthermore, both Siaα2–3 and 
Siaα2–6 linkages were found in all tissues analyzed (Figure 2) and showed a slightly 
different distribution. While porcine aortic or pulmonary valve cusps expressed higher levels 
of Siaα2–6 (SNA reactivity) compared to Siaα2–3 (MAL-II reactivity) (Figure 2A–B), the 
porcine and bovine pericardia showed a reversed expression pattern with Siaα2–3 
expression more pronounced (Figure 2C–D). Overall, this immunological analysis revealed 
qualitative differences in Sia expression between the various cardiac tissues, with all 
showing Neu5Gc expression.
Sias can be further diversified with O-acetyl groups at positions C-4, C-7, C-8 or C-9 
(Figure 3A) potentially adding to immunogenic Sia determinants. To directly identify and 
quantitate the various Sias (Neu5Ac, Neu5Gc and their O-Acetylation derivatives) in the 
valve cusps and pericardium, we further analyzed the homogenates by a sensitive 
fluorometric HPLC method (DMB-HPLC). In this analysis, Sia was released from 
glycoconjugates by mild acid hydrolysis followed by labeling with the fluorogenic reagent 
1,2-diamino-4,5-methylenedioxybenzene (DMB) that reacted with α-keto acids (Figure 3B). 
DMB-labeled Sias were then separated on reverse-phase HPLC according to their 
hydrophobicity (e.g. Neu5Ac is more hydrophobic compared to its hydroxylated derivative 
Neu5Gc, thus migrating slower on the column; Figure 3C) using Sia-derivatives released 
from bovine submaxillary mucin (BSM) as reference for Sia type characterization (Figure 
3B) [41]. Direct quantification of Sia by DMB-HPLC analysis revealed Neu5Gc expression 
in all xenogenic cardiac tissues assessed (Figure 4), confirming the previous immunological 
analysis (Figures 1 and 2). Furthermore, both porcine pericardium and bovine pericardium 
expressed four-fold higher Neu5Gc levels (416.3±17.8 pmol Sia/mg tissue; n=2, mean ± 
SEM of values in each of the pericardia; Figure 4C-D) compared to the porcine aortic/
pulmonary valve cusps (101.8±17 pmol Sia/mg tissue; n=2, mean ± SEM of values in each 
of the valve cusps; Figure 4A-B). In addition, a considerably increased Neu5Ac expression 
(82.3±2.3 %; n=4, mean ± SEM of values in each of the tissues) compared to Neu5Gc 
(15.6±3.5 %; n=4, mean ± SEM of values in each of the tissues) were found in all tissues 
corresponding to a roughly six-fold difference (6.4±1.7; n=4, mean ± SEM of values in each 
of the tissues); O-Acetylated Neu5Gc was lacking in all tissues, while very low O-
Acetylated Neu5Ac (4.3±3.5 %; n=2, mean ± SEM of values in each of the tissues) was 
found only in the porcine valves but not in porcine and bovine pericardia (Figure 4A–D). 
Altogether, our data demonstrate that Neu5Gc is an integral part of porcine/bovine cardiac 
tissues, especially in pericardium, that serve as the source for commercial BHV implanted in 
patients.
Characterization of Neu5Gc antigen in clinically used commercial BHV
During manufacturing of BHV for clinical use, the animal-derived cardiac tissues are often 
processed to reduce immunogenicity and extend preservation (Table I). This may include 
pretreatment with: glutaraldehyde, formaldehyde and ethanol, anti-calcification and 
phospholipid-reduction treatments [1,43]. To determine Neu5Gc expression in various 
commercial BHV, six commercial commonly used BHV made up of porcine aortic valve 
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(Mosaic) or porcine, bovine or equine pericardium were analyzed (Table I). Initial 
qualitative analysis of BHV homogenates showed all six samples express Neu5Gc, α-Gal 
(IB4) and both Siaα2–3 and Siaα2–6 linkages (Figure 5A). Interestingly, Neu5Gc RFU 
seemed 3 fold higher compared to α-Gal (3.3±0.5; n=6, mean ratio (Neu5Gc/IB4) ± SEM), 
however the values are not normalized according to a common standard curve. Those made 
of pericardium displayed four fold higher levels of Siaα2–3 (MAL-II) compared to Siaα2–6 
(SNA) (3.7±0.6; n=5, mean ratio (Siaα2–3/Siaα2–6) ± SEM). This was consistent with the 
analysis of porcine and bovine pericardium (Figure 4C-D). Similarly, the Mosaic BHV made 
of porcine heart valve had higher levels of Siaα2–3, albeit to a lower extent (1.6 fold Siaα2–
3 over Siaα2–6; Figure 5A). Interestingly, BHV from the same source showed different 
levels of lectin binding, probably reflecting differential BHV pretreatment during 
manufacturing (Figure 5A), or alternatively could be a consequence of different sources of 
cattle used. Hence, Mitroflow PRT that showed reduced Siaα2–3/6 compared to the original 
Mitroflow BHV, is known to be pre-treated with octanediol (amphipatic long chain alcohol 
with a hydrophobic tail and a hydrophilic head) to remove phospholipids that likely also 
affects sialo-glycoproteins or sialo-glycospingolipids content. BHV were more difficult to 
process compared with the fresh tissues, yet we used optimized equal amounts of protein in 
these qualitative measurements. This may result in underestimation of Sia in BHV compared 
with the fresh tissues using these assays. To directly characterize and quantify Neu5Gc and 
Neu5Ac expression in the BHV, DMB-HPLC analysis was performed. In this assay 
complete release of the total Sia is achieved and therefore provide a more accurate 
quantitative comparison between the different samples. This showed that regardless of the 
tissue source or the BHV processing procedure (Table I), Neu5Gc remained expressed 
(193.8±167.8 pmol Sia/μg protein; n=6, mean±SEM; Figure 5B), albeit at two-fold lower 
levels compared to the native xenogenic cardiac tissues (Figure 4C–D). Similar to the 
porcine and bovine native tissues, commercial BHV expressed higher levels of Neu5Ac 
(88.3±1.1 %) compared to Neu5Gc (11.6±1.1 %), corresponding to an eight-fold difference 
(8.0±0.7; Figure 5B). Thus, Neu5Gc is clearly expressed in the tested commercial BHV, 
despite pre-processing (Table I) for reduced immunogenicity. Yet it is possible that different 
batches of the same BHV brand would express variable levels of Sia.
Human anti-Neu5Gc IgG reactivity against commercial BHV
Humans express variable levels of serum anti-Neu5Gc antibodies (IgG, IgA, and IgM) 
recognizing multiple Neu5Gc-containing epitopes [34]. Sera from three individual healthy 
donors with anti-Neu5Gc IgG reactivity (data not shown) showed binding to porcine and 
bovine cardiac tissues (Figure 6). Human serum immunoglobulins could potentially 
recognize immunogenic epitopes also on commercial BHV, and some of it may be related to 
Neu5Gc/anti-Neu5Gc recognition. Therefore, polyclonal anti-Neu5Gc IgG was affinity-
purified from clinical remnants of IVIG that is human IgG pooled from thousands of healthy 
donors, thus reflecting the average population reactivity. The specificity of the purified 
antibodies was determined on a glycan microarray representing the various cell surface 
sialoglycans, presenting multiple Siaα2–3/6 glycans with terminal Neu5Ac or Neu5Gc and 
their O-Acetylated derivatives (Figure 7A). The antibodies show a very strong specificity to 
Neu5Gc-glycans and, as expected, no cross-reactivity with the matching Neu5Ac-glycans, 
despite the fact that the only difference between matched pairs of Neu5Ac/Neu5Gc-glycans 
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is a single oxygen atom on C-5 (Figure 3A). In addition, the polyclonal antibodies recognize 
Neu5Gcα2–3/6-linked, with or without C-9 O-Acetylation (Figure 7A). Subsequently, we 
tested the binding of these highly specific human anti-Neu5Gc IgG antibodies to the 
commercial BHV homogenates, revealing they could all be recognized (Figure 7B). Of note, 
the Mitroflow PRT showed reduced anti-Neu5Gc IgG binding compared to other BHV. Yet 
despite the much higher Neu5Ac expression and the overall reduction in Neu5Gc content on 
the commercial BHV compared to the native xenogenic cardiac tissues, it seemed that the 
manufacturing process did not eliminate the antibodies binding to Neu5Gc on commercial 
BHV.
Discussion
Here we qualitatively and quantitatively demonstrate Neu5Gc expression in various animal-
derived cardiac tissues and in six commercial BHV used in the clinic. We further show that 
highly specific human anti-Neu5Gc IgG antibodies recognize Neu5Gc-xeno-antigens 
present on six commercial BHV tested. Altogether these findings support a role of Neu5Gc 
and anti-Neu5Gc antibodies in BHV immunogenicity, which may be involved in progressive 
tissue failure. Although SVD occurs early in some bioprostheses, it is generally considered 
to begin 7 to 8 years after implantation and its occurrence increases rapidly after 10 years 
[44]. Age is a clear factor of SVD that ensues earlier in young patients. Progressive valve 
stenosis related to fibrosis and leaflets calcification are the main causes of SVD, while 
leaflet tear with acute or subacute valvular regurgitation is less frequent [44]. According to 
current knowledge, SVD mechanism can be due to 3 different biological processes: First, 
glutaraldehyde treatment to reduce antigenicity of xenogeneic bioprosthetic tissue may 
predispose it to a passive degenerative process with calcium crystal formation, and 
accumulation is partially prevented by anti-calcification treatment; Second, the 
atherosclerotic process involved at least in part in native aortic valve degeneration, is also 
likely playing a role in bioprosthesis SVD. In support, recent studies demonstrated a relation 
between classical cardiovascular risk factors such as diabetes, metabolic syndrome, 
dyslipidemia, or smoking and SVD; Third, and as suggested in the present study, 
bioprosthetic valve tissue does remain immunogenic, and this immunogenicity might elicit, 
or at least participate in, an inflammatory process that promotes progressive tissue 
degeneration [44].
Species-specific molecules in xenografts are recognized as immunogenic non-self and elicit 
an immune response to eliminate these targets [45]. Clinically used BHV are made of 
animal-derived cardiac tissues that are processed to reduce immunogenicity, but are 
nevertheless relatively short-lived [1]. In addition to protein xeno-antigens, carbohydrate 
antigens also play a major role and include the α-Gal [16] or non-Gal immunogens 
[5,24,25,46,47]. Neu5Gc had been suggested to be a major non-Gal xeno-antigen in BHV 
[1,27-29,46], thus prompting further in-depth investigation.
Here, for the first time, we conclusively demonstrated and quantitated Neu5Gc expression in 
porcine and bovine cardiac tissues as well as in six commercial BHV from 3 different 
species, namely porcine, bovine and equine (of note, we tested one sample of each BHV). 
Analysis of native pericardium and BHV made of pericardium showed specific Sia-linkage 
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preferences towards Siaα2–3>Siaα2–6, which may become important for future therapeutic 
approaches (e.g. for designing potent inhibitors for specific immune reactants). In all cardiac 
tissues Neu5Gc was markedly lower than Neu5Ac and yet preserved its immunogenicity 
allowing recognition by polyclonal human anti-Neu5Gc IgG representing the average 
population response. Thus, Neu5Gc-glycoconjugates are likely candidates to become a 
major factor contributing to BHV deterioration in patients. Quantification of xeno-antigens 
in BHV is important for quality control, risk evaluation and patients’ confidence in BHV 
choice. While BHV had been used in the clinic for many years, the major α-Gal xeno-
antigen had only recently been quantitated [19]. Quantification of Neu5Gc in commercial 
BHV performed in this work is of clear importance and provides initial lead to manage its 
immunogenicity, as would be for other potential antigenic structures. Neu5Gc and α-Gal are 
both carbohydrate xeno-antigens. However, while α-Gal is represented by the single glycan 
Galα1–3Gal, Neu5Gc-containing antigens encompass a large collection of xeno-antigens 
epitopes with terminal Neu5Gc [27,32,34], some represented on the sialoglycan microarray 
(Figure 7A). Adding to the complexity, both xeno-antigens can be conjugated to proteins or 
lipids that may further affect their immunogenicity [27]. Interestingly, Neu5Gc-containing 
glycosphingolipids were not detected in porcine heart valve cusps [24] suggesting Neu5Gc-
antigens are mainly on glycoproteins. It would be interesting to further investigate Neu5Gc 
content specifically in collagen that is a major glycoprotein constituent in BHV tissue. In 
addition, investigating batch-to-batch variability in xenoantigens expression on commercial 
BHV is warranted.
All humans have pre-existing circulating IgA/IgG/IgM antibodies against glycoconjugates 
with terminal α-Gal or Neu5Gc. Yet, anti-Neu5Gc antibodies are quite diverse in their levels 
and binding patterns between individuals, some circulate at very high levels [34]. The co-
localization of each xeno-antigen and its corresponding anti-Neu5Gc antibodies within a 
given patient likely mediates the potential deleterious effects of immune response against the 
xenografts by chronic inflammation or by various routes (e.g. immune complex formation, 
atherosclerosis-like, etc) [28,45]. α-Gal/anti-Gal antibodies had been shown to mediate 
inflammation leading to increased BHV calcification [21,48,49], and implanted BHV further 
induced anti-Gal response [18,21]. It had already been shown that co-existing Neu5Gc/anti-
Neu5Gc antibodies mediate chronic inflammation in cancer [36,37] and atherosclerosis [35]. 
Likewise, it is possible that chronic inflammation mediated by Neu5Gc/anti-Neu5Gc 
antibodies would potentially be involved in BHV deterioration in patients. Thus both anti-
Gal antibodies and anti-Neu5Gc antibodies may contribute to valve deterioration. Of note, 
either pre-existing anti-Neu5Gc antibodies or those possibly induced after exposure to 
xenograft may contribute to the process of valve deterioration. Therefore, evaluation of anti-
Neu5Gc antibodies in patients before and after BHV surgery could possibly allow to better 
evaluate associated risks. The difficulties in obtaining allografts naturally prompted search 
of improved xenograft, in which most antigens had been removed either chemically or by 
generating unique knockout strains that lack xeno-antigen expression, including the α-Gal-
deficient [22,49] and the double-knockout α-Gal/Neu5Gc-deficient porcine strains [50], that 
are currently being investigated [1]. It would be interesting to test the presence of these 
antigens in those strains especially in valve and pericardium. Future studies are required to 
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evaluate the role of Neu5Gc immunogenicity in human patients and its potential role in 
bioprosthesis SVD.
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Immunohistochemical investigation of porcine and bovine tissues using anti-Neu5Gc 
antibody. (A) Porcine aortic valve cusp negative control. Porcine aortic valve cusp (B) and 
pericardium (C) and bovine pericardium (D) were stained for Neu5Gc. Arrows show the 
endothelium (A, B) and epicardium (C, D) and arrowheads show a small artery (C) and a 
capillary (D) with a strong staining of their endothelium while the muscular cells are 
completely negative. Fragments of tissues were used for analysis; data is representative of at 
least two independent experiments.
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Characterization of sialic acids in xenogenic cardiac tissues by ELISA. Tissue homogenates 
of native porcine aortic valve cusp (A), pulmonary valve cusp (B), pericardium (C), and 
bovine pericardium (D) were coated onto a 96-well plate and analyzed with anti-Neu5Gc 
IgY (Neu5Gc), biotinylated-SNA lectin or biotinylated-MAL-II lectin (detect α2–6-linked 
or α2–3-linked sialic-acids, respectively), washed then detected with HRP-anti-chicken IgY 
or HRP-streptavidin, respectively. All tissue samples express Neu5Gc, with higher levels in 
pericardium compared to valve cusps (at least two different samples from each tissue were 
tested, data represent three independent experiments; mean ± SEM).
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Sialic acids analysis by DMB-HPLC of Bovine Submaxilary Mucins (BSM). (A) Schematic 
representation of Sia structure, the backbone carbons are numbered C-1 through C-9. The 
carboxylate group R1 is negatively charged at neutral pH; Sia is linked to underlying glycans 
through R2; R5 marks the difference between Neu5Gc (R5=OH) and Neu5Ac (R5=H). 
Positions R4, R7, R8, R9 can either carry hydroxyl or be modified with O-acetyl group. (B) 
Sia derivatized with 1,2-diamino-4,5-methylenedioxybenzene (DMB) becomes fluorescent. 
(C) Sialic acids profile of Bovine Submaxilary Mucins. BSM was hydrolyzed by mild acid 
hydrolysis (2 M acetic acid that preserves O-Acetylation) then DMB-derivatized and 
analyzed by reverse-phase HPLC. The analysis shows unique fluorescence peaks for each 
type of Sia at different retention times, based on hydrophobicity.
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Quantitative analysis of sialic acids in xenogenic cardiac tissues by DMB-HPLC. Neu5Ac, 
Neu5Gc and their O-Acetylated derivatives were quantified by DMB-HPLC in native 
porcine aortic valve cusp (A), pulmonary valve cusp (B), and pericardium (C), and bovine 
pericardium (D). 2 μl of tissue homogenates were acid hydrolyzed to release Sia followed by 
DMB-labeling and HPLC analysis. Sia content was quantified according to a standard curve 
of purified Neu5Ac. Percentage of each Sia from the total detected is indicated on the charts. 
All detected O-Acetylation types were summarized (at least two different samples from each 
tissue were tested, data represent at least two independent experiments; mean ± SEM).
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Analysis of Sia expression in commercial BHV by microarray and by DMB-HPLC. (A) 
Indicated BHV homogenates (100 ng/μl) were printed at ten replicates on epoxide-coated 
slides and detected for Neu5Gc, α-Gal, α2–3-linked or α2–6-linked sialic acids by Cy3-
anti-Neu5Gc IgY (Neu5Gc) or biotinylated-IB4/MAL-II/SNA lectins, respectively, and 
binding detected by Cy3-strepavidin. Intensity unit are Relative Fluorescence Units (RFU; 
representing fluorescence at 532 nm after local background subtraction (representative of 
two independent experiments; mean ± SD). All BHV showed more Neu5Gc than α-Gal and 
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more Siaα2–3 than Siaα2–6. (B) BHV homogenates were acid hydrolyzed with sulfuric 
acid and analyzed by DMB-HPLC for quantifying Neu5Ac and Neu5Gc (single BHV 
samples of each brand; two independent experiments; mean ± SEM). Neu5Gc is clearly 
detected in all tested BHV.
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Human sera reactivity with porcine and bovine cardiac tissues. Tissue samples from native 
porcine aortic valve, pulmonary valve, and pericardium, and bovine pericardium were coated 
on 96-well microplates (1 μg/well) and serum of three individual healthy human donors 
(HS1, HS2, HS3) were tested at 1:100 dilution (two independent experiments; mean ± 
SEM).
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Binding of affinity-purified polyclonal human anti-Neu5Gc IgG on sialic acid glycan-
microarray and BHV microarray. Human anti-Neu5Gc IgG were affinity-purified from 
clinically used IVIG (pooled human IgG). 40 ng/μl were tested on glycan microarray (A) 
and BHV microarray (B) followed by detection with Cy3-anti-human IgG (Intensity unit are 
Relative Fluorescence Units (RFU; representing fluorescence at 532 nm after local 
background subtraction; representative of two independent experiments; mean ± SD)
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Table I
List of bioprosthetic heart valves (BHV) used in this study.
Manufacturer Name of BHV Animal source Bioprosthesis treatment
1 Medtronic Mosaic Porcine aortic valves Glutaraldehyde and alpha amino oleic acid
2 St Jude Medical TRIFECTA *
Bovine and porcine pericardium
Linx™ AC Technology (proprietary anti-calcification 
treatment)
3 Sorin Solo Smart Bovine pericardium Homocysteic acid
4 Sorin Mitrofow PRT Bovine pericardium Octanediol
5 Sorin Mitrofow Bovine pericardium Glutaraldehyde
6 Medtronic ATS 3f Equine pericardium Glutaraldehyde
*
The TRIFECTA valve (St. Jude Medical) is a three-leaflet stented bovine pericardial valve designed for supra-annular placement in the aortic 
position. In TRIFECTA, the valve leaflets are made of bovine pericardium. The stent, excluding the sewing cuff, is covered with porcine 
pericardium
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